Title :

Risk of progressive multifocal leukoencephalopathy in the combination antiretroviral therapy era in the french hospital database on human immunodeficiency virus (anrs-c4)

Author(s) :

Melliez, Hugues [Auteur]
Mary-Krause, Murielle [Auteur]
Bocket, Laurence [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Guiguet, Marguerite [Auteur]
Abgrall, Sophie [Auteur]
De Truchis, Pierre [Auteur]
Katlama, Christine [Auteur]
Martin-Blondel, Guillaume [Auteur]
Henn, Aurelia [Auteur]
Revest, Matthieu [Auteur]
Robineau, Olivier [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Khuong-Josses, Marie-Aude [Auteur]
Canestri, Anna [Auteur]
De Castro, Nathalie [Auteur]
Joly, Véronique [Auteur]
Mokhtari, Saadia [Auteur]
Risso, Karine [Auteur]
Gasnault, Jacques [Auteur]
Costagliola, Dominique [Auteur]

Journal title :

Clinical infectious diseases . an official publication of the Infectious Diseases Society of America

Abbreviated title :

Clin. Infect. Dis.

Publication date :

2018-04-04

ISSN :

1537-6591

English keyword(s) :

combination antiretroviral therapy
geographic origin
progressive multifocal leukoencephalopathy
hepatitis C virus
injection drug use

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Risk factors for progressive multifocal leukoencephalopathy (PML) in individuals with human immunodeficiency virus (HIV) infection are poorly documented in the era of combination antiretroviral therapy (cART). We studied ...
Show more >Risk factors for progressive multifocal leukoencephalopathy (PML) in individuals with human immunodeficiency virus (HIV) infection are poorly documented in the era of combination antiretroviral therapy (cART). We studied HIV-1-infected individuals aged ≥15 years who had no history of PML and were prospectively followed up between 1997 and 2011 in the French Hospital Database on HIV (FHDH-ANRS CO4) cohort. Cox models were used to calculate adjusted hazard ratios (HRs), focusing on sub-Saharan origin, suggested to be protective, and recent cART initiation, potentially associated with an increased risk of PML. PML developed in 555 individuals, in 57 during the first 6 months of cART. From 1997-2000 to 2009-2011, the incidence fell from 1.15 (95% confidence interval [CI], .98-1.31) to 0.49 (.37-.61) per 1000 person-years. Sub-Saharan African origin had no clear influence (HR, 0.80; 95% CI, .58-1.11). Compared with men who have sex with men, injection drug users (IDUs) were at higher risk (HR, 1.80 [95% CI, 1.32-2.45] for male and 1.68 [1.13-2.48] for female IDUs). When IDUs were excluded, hepatitis C virus seropositivity was associated with an increased risk (HR, 1.40; 95% CI, 1.02-1.93). Compared with no cART initiation, initiation <6 months previously was associated with PML onset (HR, 4.91; 95% CI, 2.42-9.95). Recent cART initiation is associated with an increased risk of PML, as are injection drug use and hepatitis C virus seropositivity. Sub-Saharan African origin had no protective effect.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• Laboratoire de virologie - ULR 3610
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T18:18:47Z